Anaxsys secures £1m funding for respiratory sensor technology

15 Oct 2010

Anaxsys Ltd has secured £1 million additional investment to accelerate the commercialisation of novel respiratory devices based on its patented sensor technology.

Deryk Williams, CEO of Anaxsys said, “This additional investment will allow Anaxsys to accelerate the commercialization of respiR8, our first product to market, and further the development of a range of innovative respiratory devices based on our core sensor technology.

"Anaxsys’ respiratory devices are developed with clinicians and healthcare professionals in mind from the onset and have the potential to revolutionise clinical practice. Our patented sensor technology enables innovative respiratory devices that provide accurate, reliable, simple to use and cost effective means to significantly improve patient outcomes.”

Jason Gould, Fund Principal of South East Growth Fund said, “The achievement of the CE Mark for respiR8 continuous respiratory rate counter is a very significant milestone for the Company. It will allow Anaxsys to implement their plans for full commercialisation of respiR8 to the UK and European healthcare markets.

"Having consulted and collaborated with clinicians and other healthcare professionals, Anaxsys identified that there is a great unmet clinical need for respiratory rate monitoring, particularly in perioperative environments, which respiR8 is ideally suited in addressing. And clinical trials and studies of the device have confirmed its effectiveness and commercial potential with healthcare professionals.”

The investors who participated in the funding include South East Growth Fund, Early Advantage Partnership and a number of business angels. Anaxsys has received £5.7m of funding to date, which includes £700,000 in grant finance.


To top